当前位置: X-MOL 学术J. Clin. Invest. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Adding chimeric antigen receptor-induced killer cells to the medical oncology shelf.
The Journal of Clinical Investigation ( IF 15.9 ) Pub Date : 2019-12-02 , DOI: 10.1172/jci132536
Brigett D Brandjes , Marco L Davila

With the approval of CD19-targeted chimeric antigen receptor (CAR) T cells for the treatment of B cell malignancies, clinicians have gained valuable insights into the power and challenges of cellular therapies. In this issue of the JCI, Maluski et al. showed that a CAR containing a CD28 costimulatory domain drives progeny differentiation to resemble that of NK cells, which have the potential for an off-the-shelf cell therapy. These CAR-induced killer (CARiK) cells displayed potent antitumor function and killed across the MHC barrier in vivo. After performing in vitro and in vivo mouse studies, the authors also successfully differentiated human umbilical cord blood-derived progenitor cells into CARiK cells. These unique cells may address some of the current challenges associated with first-generation CARs, such as prolonged production that requires patients to wait weeks for infusion. We believe this innovative progenitor gene-engineered lymphoid system has the potential for clinical translation.

中文翻译:

将嵌合抗原受体诱导的杀伤细胞添加到医学肿瘤学架子上。

随着 CD19 靶向嵌合抗原受体 (CAR) T 细胞被批准用于治疗 B 细胞恶性肿瘤,临床医生对细胞疗法的力量和挑战有了宝贵的见解。在本期 JCI 中,Maluski 等人。表明含有 CD28 共刺激结构域的 CAR 可驱动后代分化为类似于 NK 细胞的分化,NK 细胞具有现成细胞疗法的潜力。这些 CAR 诱导的杀伤 (CARiK) 细胞显示出强大的抗肿瘤功能,并在体内通过 MHC 屏障被杀死。在进行体外和体内小鼠研究后,作者还成功地将人脐带血来源的祖细胞分化为 CARiK 细胞。这些独特的细胞可以解决当前与第一代 CAR 相关的一些挑战,例如需要患者等待数周才能输液的长时间生产。我们相信这种创新的祖细胞基因工程淋巴系统具有临床转化的潜力。
更新日期:2019-12-03
down
wechat
bug